Apport du PSA et de sa densité dans le diagnostic et le dépistage du cancer de la prostate

Souiden, Yousra; Elkamel, R.; Mahdouani, Manel; Mahdouani, Kacem

doi:10.1684/abc.2010.0481

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PSA which is a serine protease produced by the prostate epithelium is not specific for prostate cancer, but rather for the prostate organ. In fact, an increase in the PSA level can be found in patients developing prostate cancer as well as in patients with benign prostatic pathologies (such as benign adenomyomatous hyperplasia of the prostate, prostate inflammation etc…) [9].  Discrepancy between first and second reading In our study, 8.3% of cases (5/60) presented a discrepancy between the first and second reading.…”

Section:  Psa Levelmentioning

confidence: 48%

Contribution of Anti-p63 Antibodies in the Interpretation of Benign Label Prostatic Biopsies

Thiam,

Senghor,

Codja

et al. 2024

OJPathology

View full text Add to dashboard Cite

Introduction: Prostate cancer is the second most common cancer in men. The diagnosis is most often based on the prostate biopsies' analysis and on histological criteria recognizable on standard coloring. In some cases, the use of immunohistochemistry is important. Objectives: This paper aims to specify the p63 phenotypic profile of lesions diagnosed benign, with minimal suspect foci, difficult to interpret, HGPIN (high grade intraepithelial neoplasia) and LGPIN (low-grade prostatic intraepithelial neoplasia) and evaluate the manual technique of p63 immunohistochemistry. Patients and Method: This was a retrospective, descriptive study of prostate biopsies recorded in the PAC service of the HALD from January 1st, 2018 to December 31st, 2018. It was completed by a manual immunohistochemical study of the blocks enrolled from November 19th to December 4th, 2020 in the PAC department of the HPD. The studied parameters were: registry number, age, clinical stage, prostate volume, PSA level, microscopic appearance and p63 immunohistochemical profile. Results: Our study included 60 prostate biopsies. The ages of our patients varied from 45 to 77 years, with an average of 64.2 years and a standard deviation of 6.2. The majority of patients were at clinical stage cT2b (33%) with a prostate volume varying between 33.15 and 169.4 cc. The minimum value of PSA in our series is 5 ng/ml, the maximum being 100 ng/ml with an average level of 24.1 ng/ml and a standard deviation of 21.2. Our series included 50 adenomyomatous hyperplasias, 7 adenomyomatous hyperplasias associated with chronic prostatitis, 2 HGPIN and 1 LGPIN. After re-reading we found 5 discordant cases, which corresponded to minimal suspect foci (kappa = 0.5098). The p63 marking was informative in 53 cases, i.e. 88%, and non-informative in 7 cases, i.e. 12%. Among the uninformative markings, 2 were due to lack of tissue adhesion to the slides.

show abstract

Section:  Psa Levelmentioning

confidence: 48%